AutoCD6-CAR Treg cells

Phase 1Small molecule

AutoCD6-CAR Treg cells is one of 53 small molecule programs targeting Type 1 Diabetes Mellitus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 Diabetes MellitusNot yet recruiting

Type 1 Diabetes MellitusPhase 1

Not yet recruiting

Competition

Competitive Landscape

64 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

2 2

Mounjaro

Eli Lilly

Approved

1 3

Olumiant

Prevacid

Diabeta

Cellcept

Calciferol

Opzelura

Neoral

Rocaltrol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Type 1 Diabetes Mellitus

NCT07395050

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

A Pilot Study to Evaluate the Safety, Tolerability, and Feasibility of Autologous Anti-CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Stage 3 Type 1 Diabetes

Not yet recruiting·CCity of Hope Medical Center·Phase 1·NCT07395050·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AutoCD6-CAR Treg cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AutoCD6-CAR Treg cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AutoCD6-CAR Treg cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCity of Hope Medical Center

AutoCD6-CAR Treg cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News